Mak, Lung-Yi
Hoang, Joseph
Jun, Dae Won
Chen, Chien-Hung
Peng, Cheng-Yuan
Yeh, Ming-Lun
Kim, Sung Eun
Huang, Daniel Q.
Jeong, Jae Yoon
Yoon, Eileen
Oh, Hyunwoo
Tsai, Pei-Chien
Huang, Chung-Feng
Ahn, Sang Bong
Trinh, Huy
Xie, Qing
Wong, Grace L. H.
Enomoto, Masaru
Shim, Jae-Jun
Lee, Dong-Hyun
Liu, Li
Kozuka, Ritsuzo
Cho, Yong Kyun
Jeong, Soung Won
Kim, Hyoung Su
Trinh, Lindsey
Dao, Allen
Huang, Rui
Hui, Rex Wan-Hin
Tsui, Vivien
Quek, Sabrina
Khine, Htet Htet toe Wai
Ogawa, Eiichi
Dai, Chia Yen
Huang, Jee Fu
Cheung, Ramsey
Wu, Chao
Chuang, Wan-Long
Lim, Seng Gee
Yu, Ming-Lung
Yuen, Man-Fung
Nguyen, Mindie H. http://orcid.org/0000-0002-6275-4989
Article History
Received: 20 September 2021
Accepted: 30 October 2021
First Online: 25 November 2021
Declarations
:
: CYP: Consulting/ Advisory board member: Abbvie, Bristol Myers Squibb, Gilead Sciences, Roche. DQH: Research grant: Exxon Mobil-NUS Fellowship, NMRC Research Training Fellowship. HT: Research grant: Gilead Sciences, Intercept, Target; Consulting/ advisory board: Gilead Sciences; Speaker fees: Gilead Sciences; Stock ownership: Gilead Sciences. GLHW: Research grant: Gilead Sciences; Consulting/ advisory board: Gilead Sciences, Janssen; Speaker fees: Abbott, Abbvie, Bristol Myers Squibb, Gilead Sciences. DHL: Research grant: Bristol Myers Squibb Korea, Gilead Sciences (Korea), Janssen Korea, Korea Pharma. EO: Speaker fees: Gilead Sciences. CYD: Speaker fees: Abbvie, Merck Sharp and Dohme, Gilead Sciences, Roche, Bristol Myers Squibb. WLC: Consulting: Gilead Sciences, Abbvie, Bristol Myers Squibb, Merck Sharp and Dohme, PharmaEssentia; Speaker fees: Gilead Sciences, Abbvie, Bristol Myers Squibb, Merck Sharp and Dohme, PharmaEssentia. MLY: Research grant: Abbott, Bristol Myers Squibb, Gilead Sciences, Merck Sharp and Dohme; Consulting: Abbvie, Abbott, Ascletis, Bristol Myers Squibb, Gilead Sciences, Merck Sharp and Dohme, Roche; Speaker fees: Abbvie, Abbott, Bristol Myers Squibb, Gilead Sciences, Merck Sharp and Dohme, IPSEN. MFY: Research funding: Assembly Biosciences, Arrowhead Pharmaceuticals, Bristol Myer Squibb, Fujirebio Incorporation, Gilead Sciences, Merck Sharp and Dohme, Springbank Pharmaceuticals, Sysmex Corporation; advisory board member: Abbvie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals. MHN: Research grant: Gilead, Vir; Consulting/advisory board: Novartis, Spring Bank, Janssen, Gilead, Exact Sciences, Eli Lilly. All other authors have disclosed no personal conflict of interests in regards to the content of this paper.
: The study was conducted in accordance with the ethics principles of the Declaration of Helsinki in 1975, as revised in 2008, and was approved by the Institutional Review Board of Stanford University and at each participating institution.
: Not applicable.